Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. More Details
No risks detected for CO from our risk checks.
Flawless balance sheet and undervalued.
Share Price & News
How has Global Cord Blood's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CO has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CO underperformed the US Healthcare industry which returned 17.2% over the past year.
Return vs Market: CO underperformed the US Market which returned 10.9% over the past year.
Price Volatility Vs. Market
How volatile is Global Cord Blood's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall StDid Global Cord Blood Corporation's (NYSE:CO) Recent Earnings Growth Beat The Trend?
1 year ago | Simply Wall StWith An ROE Of 7.8%, Can Global Cord Blood Corporation (NYSE:CO) Catch Up To The Industry?
2 years ago | Simply Wall StGlobal Cord Blood Corporation (NYSE:CO): The Return Story
Is Global Cord Blood undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CO ($3.27) is trading below our estimate of fair value ($13.73)
Significantly Below Fair Value: CO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CO is good value based on its PE Ratio (5.5x) compared to the US Healthcare industry average (21.2x).
PE vs Market: CO is good value based on its PE Ratio (5.5x) compared to the US market (17.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CO is good value based on its PB Ratio (0.7x) compared to the US Healthcare industry average (2.6x).
How is Global Cord Blood forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Global Cord Blood has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine whether Global Cord Blood is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Global Cord Blood competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has Global Cord Blood performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CO has high quality earnings.
Growing Profit Margin: CO's current net profit margins (40.3%) are higher than last year (31.8%).
Past Earnings Growth Analysis
Earnings Trend: CO's earnings have grown significantly by 37.2% per year over the past 5 years.
Accelerating Growth: CO's earnings growth over the past year (51.6%) exceeds its 5-year average (37.2% per year).
Earnings vs Industry: CO earnings growth over the past year (51.6%) exceeded the Healthcare industry 31.1%.
Return on Equity
High ROE: CO's Return on Equity (12.5%) is considered low.
How is Global Cord Blood's financial position?
Financial Position Analysis
Short Term Liabilities: CO's short term assets (CN¥5.8B) exceed its short term liabilities (CN¥580.0M).
Long Term Liabilities: CO's short term assets (CN¥5.8B) exceed its long term liabilities (CN¥2.8B).
Debt to Equity History and Analysis
Debt Level: CO is debt free.
Reducing Debt: CO has no debt compared to 5 years ago when its debt to equity ratio was 56%.
Debt Coverage: CO has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CO has no debt, therefore coverage of interest payments is not a concern.
What is Global Cord Blood current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: CO is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Tina Zheng (48 yo)
Ms. Ting Zheng, also known as Tina, serves as the Chief Executive Officer and Chief Executive Officer of Beijing Division of Global Cord Blood Corporation (formerly known as China Cord Blood Corporation) a ...
CEO Compensation Analysis
Compensation vs Market: Tina's total compensation ($USD7.32M) is above average for companies of similar size in the US market ($USD2.03M).
Compensation vs Earnings: Tina's compensation has increased by more than 20% in the past year.
|Chairperson||no data||CN¥1.03m||no data|
|CFO & Director||no data||CN¥976.87k||0.38% |
|Independent Non-Executive Director||no data||no data||no data|
|Independent Non-Executive Director||11.25yrs||no data||no data|
|Independent Non-Executive Director||11.25yrs||no data||no data|
|Independent Non-Executive Director||0.58yr||no data||no data|
|Non-Executive Director||2.67yrs||no data||no data|
|Independent Non-Executive Director||0.83yr||no data||no data|
Experienced Board: CO's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Global Cord Blood Corporation's company bio, employee growth, exchange listings and data sources
- Name: Global Cord Blood Corporation
- Ticker: CO
- Exchange: NYSE
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$397.472m
- Shares outstanding: 121.55m
- Website: https://www.globalcordbloodcorp.com
Number of Employees
- Global Cord Blood Corporation
- Bank of China Tower
- 48th Floor
- Hong Kong
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CO||NYSE (New York Stock Exchange)||Yes||Ordinary Shares||US||USD||Jul 2009|
|6CB||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jul 2009|
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, process ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/25 05:56|
|End of Day Share Price||2020/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.